As­traZeneca pon­ders a Chi­na phar­ma spin­off to pro­tect it­self from geopo­lit­i­cal fall­out — FT

As se­nior gov­ern­ment of­fi­cials in the US war­i­ly look to sta­bi­lize rocky re­la­tions with Chi­na, one glob­al phar­ma gi­ant has been con­sid­er­ing a cor­po­rate re­struc­tur­ing that could help it side­step the tense con­fronta­tion be­tween the two coun­tries that has de­vel­oped in the last few years.

The Fi­nan­cial Times is re­port­ing that As­traZeneca has been con­sid­er­ing the plus­es and mi­nus­es of spin­ning off its Chi­na as­sets in­to a sep­a­rate­ly list­ed com­pa­ny in ei­ther Hong Kong or Shang­hai. Cit­ing sev­er­al bankers fa­mil­iar with the deal, the FT high­lights the pre­lim­i­nary na­ture of the con­ver­sa­tions, not­ing that a host of multi­na­tion­als with a stake in Chi­na have been do­ing ex­act­ly the same thing. (The FT owns a ma­jor­i­ty stake in End­points News, though the news or­ga­ni­za­tions are in­de­pen­dent.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER